Patents by Inventor Yefen Zou
Yefen Zou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230348852Abstract: The present invention provides ocular cells, genetically modified by a CRISPR system targeting the expression of B2M for ocular cell therapy. The invention further provides methods of generating an expanded population of genetically modified ocular cells, for example limbal stem cells (LSCs) or corneal endothelial cells (CECs), wherein the cells are expanded involving the use of a LATS inhibitor and the expression of B2M in the cells has been reduced or eliminated. The present invention also provides cell populations, preparations, uses and methods of therapy comprising said cells.Type: ApplicationFiled: April 26, 2021Publication date: November 2, 2023Inventors: Frada BERENSHTEYN, Bo HAN, Xueshi HAO, Jessica HEYDER, Timothy Z. HOFFMAN, Qihui JIN, Arnaud LACOSTE, Jun LIU, Yahu LIU, Tingting MO, Bradley Andrew MURRAY, Daniel Joseph O’CONNELL, Jianfeng PAN, Yun Feng XIE, Shanshan YAN, Yefen ZOU
-
Publication number: 20230190751Abstract: The present invention is related to 6-6 Fused Bicyclic Heteroaryl Compounds of the Formula A2 or A1 and their Use as LATS Inhibitors, or a salt, stereoisomer or pharmaceutical composition thereof; wherein the variables are as defined herein. The present invention further relates to a method of LATS inhibition in a cell population using a compound of Formula A1, or a salt, stereoisomer or pharmaceutical composition thereof. The present invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, their use in the treatment and management of diseases or disorders.Type: ApplicationFiled: August 18, 2022Publication date: June 22, 2023Inventors: Dirk BEHNKE, Frada BERENSHTEYN, Xueshi HAO, Timothy Z. HOFFMAN, Qihui JIN, Arnaud LACOSTE, Cameron LEE, Jun LIU, Yahu A. LIU, Juergen Klaus MAIBAUM, Tingting MO, Jianfeng PAN, Xin QU, Jan TCHORZ, Yun Feng XIE, Shanshan YAN, Yefen ZOU
-
Patent number: 11458138Abstract: The present invention is related to 6-6 Fused Bicyclic Heteroaryl Compounds of the Formula A2 or A1 and their Use as LATS Inhibitors, or a salt, stereoisomer or pharmaceutical composition thereof; wherein the variables are as defined herein. The present invention further relates to a method of LATS inhibition in a cell population using a compound of Formula A1, or a salt, stereoisomer or pharmaceutical composition thereof. The present invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, their use in the treatment and management of diseases or disorders.Type: GrantFiled: April 26, 2018Date of Patent: October 4, 2022Assignee: Novartis AGInventors: Dirk Behnke, Frada Berenshteyn, Xueshi Hao, Timothy Hoffman, Qihui Jin, Arnaud Lacoste, Cameron Lee, Jun Liu, Yahu Liu, Juergen Klaus Maibaum, Tingting Mo, Jianfeng Pan, Xin Qu, Jan Tchorz, Yun Feng Xie, Shanshan Yan, Yefen Zou
-
Publication number: 20200131474Abstract: The present invention provides ocular cells, genetically modified by a CRISPR system targeting the expression of B2M for ocular cell therapy. The invention further provides methods of generating an expanded population of genetically modified ocular cells, for example limbal stem cells (LSCs) or corneal endothelial cells (CECs), wherein the cells are expanded involving the use of a LATS inhibitor and the expression of B2M in the cells has been reduced or eliminated. The present invention also provides a cell populations, preparations, uses and methods of therapy comprising said cells.Type: ApplicationFiled: October 25, 2019Publication date: April 30, 2020Inventors: Frada BERENSHTEYN, Bo HAN, Xueshi HAO, Jessica HEYDER, Timothy Z. HOFFMAN, Qihui JIN, Arnaud LACOSTE, Jun LIU, Yahu LIU, Tingting MO, Bradley Andrew MURRAY, Daniel Joseph O'CONNELL, Jianfeng PAN, Yun Feng XIE, Shanshan YAN, Yefen ZOU
-
Publication number: 20180344738Abstract: The present invention is related to 6-6 Fused Bicyclic Heteroaryl Compounds of the Formula A2 or A1 and their Use as LATS Inhibitors, or a salt, stereoisomer or pharmaceutical composition thereof; wherein the variables are as defined herein. The present invention further relates to a method of LATS inhibition in a cell population using a compound of Formula A1, or a salt, stereoisomer or pharmaceutical composition thereof. The present invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, their use in the treatment and management of diseases or disorders.Type: ApplicationFiled: April 26, 2018Publication date: December 6, 2018Inventors: Dirk BEHNKE, Frada BERENSHTEYN, Xueshi HAO, Timothy HOFFMAN, Qihui JIN, Arnaud LACOSTE, Cameron LEE, Jun LIU, Yahu LIU, Juergen Klaus MAIBAUM, Tingting MO, Jianfeng PAN, Xin QU, Jan TCHORZ, Yun Feng XIE, Shanshan YAN, Yefen ZOU
-
Patent number: 10098949Abstract: Immunopotentiators can be adsorbed to insoluble metal salts, such as aluminum salts, to modify their pharmacokinetics, pharmacodynamics, intramuscular retention time, and/or immunostimulatory effect. Immunopotentiators are modified to introduce a moiety, such as a phosphonate group, which can mediate adsorption. These modified compounds can retain or improve their in vivo immunological activity even when delivered in an adsorbed form.Type: GrantFiled: April 7, 2016Date of Patent: October 16, 2018Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Manmohan Singh, David A. G. Skibinksi, Tom Yao-Hsiang Wu, Yongkai Li, Alex Cortez, Xiaoyue Zhang, Yefen Zou, Timothy Z. Hoffman, Jianfeng Pan, Kathy Yue
-
Publication number: 20160213776Abstract: Immunopotentiators can be adsorbed to insoluble metal salts, such as aluminium salts, to modify their pharmacokinetics, pharmacodynamics, intramuscular retention time, and/or immunostimulatory effect. Immunopotentiators are modified to introduce a moiety, such as a phosphonate group, which can mediate adsorption. These modified compounds can retain or improve their in vivo immunological activity even when delivered in an adsorbed form.Type: ApplicationFiled: April 7, 2016Publication date: July 28, 2016Applicant: GlaxoSmithKline Biologicals SAInventors: Manmohan SINGH, David A.G. SKIBINKSI, Tom Yao-Hsiang WU, Yongkai LI, Alex CORTEZ, Xiaoyue ZHANG, Yefen ZOU, Timothy Z. HOFFMAN, Jianfeng PAN, Kathy YUE
-
Patent number: 9365506Abstract: The invention provides a novel class of compounds, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors 2. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine.Type: GrantFiled: July 9, 2014Date of Patent: June 14, 2016Assignee: NOVARTIS AGInventors: Tom Yao-Hsiang Wu, Yefen Zou, Timothy Z. Hoffman, Jianfeng Pan
-
Patent number: 9315530Abstract: Immunopotentiators can be adsorbed to insoluble metal salts, such as aluminum salts, to modify their pharmacokinetics, pharmacodynamics, intramuscular retention time, and/or immunostimulatory effect. Immunopotentiators are modified to introduce a moiety, such as a phosphonate group, which can mediate adsorption. These modified compounds can retain or improve their in vivo immunological activity even when delivered in an adsorbed form.Type: GrantFiled: September 1, 2011Date of Patent: April 19, 2016Assignee: Novartis AGInventors: Manmohan Singh, David A. G. Skibinski, Tom Yao-Hsiang Wu, Yongkai Li, Alex Cortez, Xiaoyue Zhang, Yefen Zou, Timothy Z. Hoffman, Jianfeng Pan, Kathy Yue
-
Patent number: 8895577Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors, including TLR7 and TLR8. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine (formula I) wherein: X3 is N; X4 is N Or CR3; X5 is —CR4?CR5.Type: GrantFiled: April 22, 2013Date of Patent: November 25, 2014Inventors: Tom Yao-Hsiang Wu, Yongkai Li, Alex Cortez, Yefen Zou, Pranab Mishra, Xiaoyue Zhang, Nicholas Valiante
-
Publication number: 20140323390Abstract: The invention provides a novel class of compounds, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors 2. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine.Type: ApplicationFiled: July 9, 2014Publication date: October 30, 2014Applicant: IRM LLCInventors: Tom Yao-Hsiang WU, Yefen Zou, Timothy Z. Hoffman, Jianfeng Pan
-
Patent number: 8808703Abstract: The invention provides a novel class of compounds viz. generally lipopeptides like Pam3CSK4, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors 2. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness a vaccine.Type: GrantFiled: March 23, 2011Date of Patent: August 19, 2014Inventors: Tom Yao-Hsiang Wu, Yefen Zou, Timothy Z. Hoffman, Jianfeng Pan
-
Publication number: 20130274465Abstract: Immunopotentiators can be adsorbed to insoluble metal salts, such as aluminium salts, to modify their pharmacokinetics, pharmacodynamics, intramuscular retention time, and/or immunostimulatory effect. Immunopotentiators are modified to introduce a moiety, such as a phosphonate group, which can mediate adsorption. These modified compounds can retain or improve their in vivo immunological activity even when delivered in an adsorbed form.Type: ApplicationFiled: September 1, 2011Publication date: October 17, 2013Applicants: IRM LLC, NOVARTIS AGInventors: Manmohan Singh, David A.G. Skibinski, Tom Yao-Hsiang Wu, Yongkai Li, Alex Cortez, Xiaoyue Zhang, Yefen Zou, Timothy Z. Hoffman, Jianfeng Pan, Kathy Yue
-
Publication number: 20130253002Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors, including TLR7 and TLR8. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine (formula I) wherein: X3 is N; X4 is N Or CR3; X5 is —CR4?CR5.Type: ApplicationFiled: April 22, 2013Publication date: September 26, 2013Inventors: TOM YAO-HSIANG WU, YONGKAI LI, ALEX CORTEZ, YEFEN ZOU, PRANAB MISHRA, XIAOYUE ZHANG, NICHOLAS VALIANTE
-
Patent number: 8466167Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors, including TLR7 and TLR8. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine (formula I) wherein: X3 is N; X4 is N Or CR3; X5 is —CR4?CR5.Type: GrantFiled: February 27, 2009Date of Patent: June 18, 2013Assignees: IRM LLC, Novartis AGInventors: Tom Yao Hsiang Wu, Yongkai Li, Alex Cortez, Yefen Zou, Pranab Mishra, Xiaoyue Zhang, David Skibinski, Manmohan Singh, Nicholas Valiante
-
Publication number: 20130065861Abstract: The invention provides a novel class of compounds viz. generally lipopeptides like Pam3CSK4, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors 2. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness a vaccine.Type: ApplicationFiled: March 23, 2011Publication date: March 14, 2013Inventors: Tom Yao-Hsiang Wu, Yefen Zou, Timothy Z. Hoffman, Jianfeng Pan
-
Publication number: 20120177681Abstract: Immunopotentiators can be adsorbed to insoluble metal salts, such as aluminium salts, to modify their pharmacokinetics, pharmacodynamics, intramuscular retention time, and/or immunostimulatory effect. Immunopotentiators are modified to introduce a moiety, such as a phosphonate group, which can mediate adsorption. These modified compounds can retain or improve their in vivo immunological activity even when delivered in an adsorbed form.Type: ApplicationFiled: September 1, 2011Publication date: July 12, 2012Inventors: Manmohan Singh, David A.G. Skibinski, Tom Yao-Hsiang Wu, Yongkai Li, Alex Cortez, Xiaoyue Zhang, Yefen Zou, Timothy Z. Hoffman, Jianfeng Pan, Kathy Yue
-
Publication number: 20110081365Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors, including TLR7 and TLR8. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine (formula I) wherein: X3 is N; X4 is N Or CR3; X5 is —CR4?CR5.Type: ApplicationFiled: February 27, 2009Publication date: April 7, 2011Applicants: IRM LLC, Novartis 35Inventors: Alex Cortez, Yongkai Li, Pranab Mishra, Manmohan Singh, David Skibinski, Nicholas Valiante, Tom Yao-Hsiang Wu, Xiaoyue Zhang, Yefen Zou